- Generic name
- Sacubitril + Valsartan
- Strength
- 24 mg + 26 mg
- Dosage form
- Tablet
- Manufactured by
- Renata PLC.
Entrovas-24/26 Tablet
About Entrovas-24/26 Tablet
Entrovas-24/26 is a tablet that combines two heart-failure medicines, sacubitril and valsartan, to help the heart work under less strain. It is used in certain people with long-term heart failure.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Entrovas-24/26 Tablet?
Entrovas-24/26 is a tablet made by Renata PLC. that contains sacubitril and valsartan. It belongs to a group of heart-failure medicines that act in two ways at once: sacubitril raises the level of natural peptides the body makes that help widen blood vessels and clear fluid, while valsartan blocks the action of angiotensin II, a substance that tightens blood vessels. Together they ease the workload on a failing heart. It is prescribed for long-term heart failure with reduced pumping ability, and for some children with symptomatic heart failure. Only a doctor can decide whether it suits a particular person.
Uses of Entrovas-24/26
Entrovas-24/26 is used to lower the risk of cardiovascular death and hospital admission in adults with long-term heart failure and reduced ejection fraction. It is also used for symptomatic heart failure with poor left-sided pumping in children aged one year and older. It is not a general blood-pressure tablet for everyone; the doctor decides whether it is appropriate.
How to use Entrovas-24/26
Take Entrovas-24/26 exactly as the doctor prescribes. The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet as directed by your doctor or pharmacist. Do not stop or change the medicine on your own, even if you feel better, and ask your doctor before taking any other medicine alongside it.
Side effects of Entrovas-24/26
Side effects that need attention include swelling of the face, lips, tongue or throat (angioedema), low blood pressure with dizziness or fainting, worsening kidney function, raised potassium, cough and dizziness. Contact your doctor promptly if you notice swelling, trouble breathing, fainting, or a big drop in urine. Ask your doctor or pharmacist about anything that worries you.
Safety and precautions
Tell your doctor about any previous swelling of the face, lips or throat, especially linked to heart or blood-pressure medicines, and about kidney or liver problems. This medicine is not used together with certain other heart and blood-pressure drugs, so give your doctor a full list of what you take. It is not recommended in severe liver impairment. Use in pregnancy should be discussed with the doctor first, and children under one year are not covered. Ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding.
Frequently asked questions
What kind of medicine is Entrovas-24/26 and what is it used for?
It is a tablet combining sacubitril and valsartan, used for long-term heart failure with reduced pumping ability, and for some children with symptomatic heart failure. The doctor decides if it is suitable for you.
What side effects should I watch for and when should I call the doctor?
Watch for swelling of the face, lips, tongue or throat, fainting, strong dizziness, or much less urine than usual. Call your doctor promptly if any of these happen, or if you feel unwell after starting the medicine.
What does the generic name sacubitril plus valsartan mean?
Sacubitril is a neprilysin inhibitor, meaning it slows the breakdown of natural peptides that help the heart and blood vessels. Valsartan is an angiotensin receptor blocker, which stops angiotensin II from tightening blood vessels. The tablet combines both actions.
Can I stop Entrovas-24/26 on my own or take other medicines with it?
Do not stop or change it without your doctor. Some medicines, including certain heart, blood-pressure and pain medicines, should not be combined with it. Give your doctor and pharmacist a full list of everything you take before adding anything new.
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ... Read more
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
Dosage & Administration
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Recommended Dose Titration-
Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
Pregnancy & Lactation
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Storage Conditions
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.